Avtor/Urednik     Jensterle Sever, Mojca; Kravos, Nika Aleksandra; Pfeifer, Marija; Kocjan, Tomaž; Janež, Andrej
Naslov     A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
Tip     članek
Vol. in št.     Letnik 14, št. 1
Leto izdaje     2015
Obseg     str. 81-90
ISSN     1109-3099 - Hormones (Athens, Greece)
Jezik     eng
Abstrakt     OBJECTIVE Long-acting glucagon-like peptide 1 receptor agonist liraglutide is linked to progressive and sustained weight loss in obese people with diabetes. However, Its efficacy and safety in women with polycystic ovary syndrome (PCOS) has not yet been addressed. DESIGN Thirty-two obese women (aged 27.6 % 7.2 years, BMI 39.5 % 6.2 kg/m2) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin). The main outcome was change in body weight. RESULTS Intention-to-treat analysis showed significant BMI (-0.98 kg/m2; p<0.001), body weight (-2.52 kg; p<0.001), waist circumference (-3.38 cm; p<0.001) and whole-body fat mass (-1.26%; p<0.001) reduction in both treatment arms without significant differences between therapeutic groups. However, in a subgroup of patients (n=9) with insulin resistance (HOMAIR >2), severe obesity and higher odds ratio for the metabolic syndrome (OR=3.9), the patients fared much better with liraglutide than with metformin (mean BMI decreased 2.13 kg/m2 vs. 0.62 kg/m2, respectively). CONCLUSIONS Short-term liraglutide treatment was associated with significant weight loss in a subset of obese patients with newly diagnosed PCOS and higher metabolic risk profile.
Proste vsebinske oznake     GLP-1 receptor agonist
liraglutide
metformin
obesity
PCOS